Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Jun;5(Suppl 3):e000820.
doi: 10.1136/esmoopen-2020-000820.

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

Antonio Passaro  1 , Alfredo Addeo  2 , Christophe Von Garnier  3 , Fiona Blackhall  4 , David Planchard  5 , Enriqueta Felip  6 , Rafal Dziadziuszko  7 , Filippo de Marinis  8 , Martin Reck  9 , Hasna Bouchaab  10 , Solange Peters  10
Affiliations
Practice Guideline

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

Antonio Passaro et al. ESMO Open. 2020 Jun.

Abstract

The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. Within this framework, it is crucial to ensure no disruption to essential oncological services and guarantee the optimal care.This is a structured proposal for the management of lung cancer, comprising three levels of priorities, namely: tier 1 (high priority), tier 2 (medium priority) and tier 3 (low priority)-defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and Magnitude of Clinical Benefit Scale.The manuscript emphasises the impact of the COVID-19 pandemic on lung cancer care and reconsiders all steps from diagnosis, staging and treatment.These recommendations should, therefore, serve as guidance for prioritising the different aspects of cancer care to mitigate the possible negative impact of the COVID-19 pandemic on the management of our patients.As the situation is rapidly evolving, practical actions are required to guarantee the best patients' treatment while protecting and respecting their rights, safety and well-being. In this environment, cancer practitioners have great responsibilities: provide timely, appropriate, compassionate and justified cancer care, while protecting themselves and their patients from being infected with COVID-19. In case of shortages, resources must be distributed fairly. Consequently, the following recommendations can be applied with significant nuances, depending on the time and location for their use, considering variable constraints imposed to the health systems. An exceptional flexibility is required from cancer caregivers.

Keywords: COVID19; SARS-CoV-2; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AP: honoraria for consulting, advisory role or lectures from AstraZeneca, Agilent/Dako, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme and Roche Genentech. AA: honoraria for consulting, advisory role from AstraZeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, Takeda, Pfizer, Roche Genentech and Boehringer Ingelheim. CvG: honoraria for consulting, advisory role or lectures from AstraZeneca, Boehringer Ingelheim, GSK, Mundipharma, Novartis, Pfizer, PneumRx et Pulmonx. FB: honoraria for consulting, advisory role or lectures from AstraZeneca, Abbvie, Bayer, Roche Genentech, Pfizer, Cell Medica, Celgene, Takeda. DP: honoraria for consulting, advisory role or lectures from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche Genentech, Samsung Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. EF: advisory role or speaker’s bureau from AbbVie, AstraZeneca, Blueprint medicines, Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, prIME Oncology, Roche Genentech, Samsung, Springer, Takeda, Touchime. Board: Grifols, independent member Research funding: Fundación Merck Salud, Grant for Oncology Innovation EMD Serono. RD: honoraria for consulting, advisory role or lectures from from AstraZeneca, Roche, Pfizer, Novartis, Seattle Genetics, Foundation Medicine, Bristol-Myers Squibb, Takeda. FdM: honoraria for consulting, advisory role or lectures from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, Novartis, Roche Genentech, Takeda and Pfizer. MR: honoraria for consulting, advisory role or lecture from Amgen, AstraZeneca, BMS, Boehringer-Ingelheim, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Samsung. Support for clinical research from BMS. HB: honoraria for consulting, advisory role or lecture for AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and Roche Genentech. SP: received education grants, provided consultation, attended advisory boards, or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda and Vaccibody, from whom she has received honoraria (all fees to institution).

References

    1. Guan WJ, ZY N, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. [Epub ahead of print: 28 Feb 2020]. - PMC - PubMed
    1. WHO COVID-19: Operational guidance for maintaining essential health services during an outbreak Interim guidance., 2020. Available: https://apps.who.int/iris/handle/10665/331561 [Accessed 21 Apr 2020].
    1. Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: Imperial College London, 2020. - PMC - PubMed
    1. Burki TH. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol 2020. - PMC - PubMed
    1. Emanuel EJ, Persad G, Upshur R. Fair allocation of scarce medical resources in the time of Covid-19. N Eng J Med 2020. - PubMed

Publication types

MeSH terms